menu search

AVRO / Avrobio: Net-Net Biotech Pursuing Strategic Alternatives

Avrobio: Net-Net Biotech Pursuing Strategic Alternatives
After monetizing one of its pipeline candidates, Avrobio has cash well in excess of its market cap. The company announced its search for strategic alternatives recently. The process could close its valuation gap soon. There is potential for significantly more value if Avrobio can also monetize its remaining candidates. Read More
Posted: Aug 12 2023, 04:03
Author Name: Seeking Alpha
Views: 102174

AVRO News  

Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?

By Zacks Investment Research
October 23, 2023

Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?

Here is how AVROBIO, Inc. (AVRO) and DaVita HealthCare (DVA) have performed compared to their sector so far this year. more_horizontal

Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?

By Zacks Investment Research
October 6, 2023

Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?

Here is how AVROBIO, Inc. (AVRO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year. more_horizontal

Avrobio: Net-Net Biotech Pursuing Strategic Alternatives

By Seeking Alpha
August 12, 2023

Avrobio: Net-Net Biotech Pursuing Strategic Alternatives

After monetizing one of its pipeline candidates, Avrobio has cash well in excess of its market cap. The company announced its search for strategic alt more_horizontal

AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%

By Zacks Investment Research
July 13, 2023

AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%

AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges more_horizontal

Why Is AVROBIO (AVRO) Stock Up 83% Today?

By InvestorPlace
May 22, 2023

Why Is AVROBIO (AVRO) Stock Up 83% Today?

AVROBIO (NASDAQ: AVRO ) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NYSE: NVS ). This deal has more_horizontal

AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study

By Benzinga
May 17, 2022

AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study

AVROBIO Inc (NASDAQ: AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a condition c more_horizontal

After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data

By Benzinga
February 9, 2022

After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data

Avrobio Inc's AVRO gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year af more_horizontal

After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data

By Benzinga
February 9, 2022

After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data

Avrobio Inc's AVRO gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year af more_horizontal


Search within

Pages Search Results: